Sorafenib: Rays of Hope in Thyroid Cancer
Author:
Affiliation:
1. Endocrine Unit, Evgenidion Hospital, University of Athens, Athens, Greece.
2. Department of Experimental and Clinical Pharmacology, University of Catania, Catania, Italy.
Publisher
Mary Ann Liebert Inc
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Link
https://www.liebertpub.com/doi/pdf/10.1089/thy.2010.0056
Reference75 articles.
1. Tyrosine Kinases as Targets for Cancer Therapy
2. The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
3. New targets and therapeutic approaches for endocrine malignancies☆
4. Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention
5. Sorafenib in Advanced Hepatocellular Carcinoma
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects;Frontiers in Endocrinology;2022-07-08
2. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation;Health Technology Assessment;2020-01
3. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects;Thyroid;2017-09
4. Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer;Current Opinion in Oncology;2017-03
5. IL-12 immunotherapy of BrafV600E-induced papillary thyroid cancer in a mouse model;Laboratory Investigation;2015-10-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3